SCM
BVS icon

Soleus Capital Management’s Bioventus BVS Stock Holding History

Soleus Capital Management’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-428,397
Closed -$6.21M – 72
2021
Q4 		$6.21M Buy
428,397
+333,795
+353% +$4.75M 0.62% 34
2021
Q3 		$1.34M Buy
+94,602
New +$1.46M 0.21% 62

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
JIC
Juniper Investment Company New York $378M AUM 95.37% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
NI
Nuance Investments Kansas City, Missouri $588M AUM 6.93% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Soleus Capital Management's BVS Position: Q1 2022 in Review

Soleus Capital Management sold out of Bioventus (BVS) in Q1 2022, closing a stake of 428,397 shares — an estimated $6.21M sold.

Soleus Capital Management first reported a position in BVS in Q3 2021 and held it in 2 quarters. The position peaked at $6.21M in Q4 2021. 105 funds tracked by Wall St. Rank hold BVS as of Q1 2022.

  • Soleus Capital Management reported no remaining Bioventus position as of Q1 2022 after selling out during the quarter.
  • Soleus Capital Management sold 428,397 Bioventus shares in Q1 2022, an estimated $6.21M.
  • Soleus Capital Management first reported a position in Bioventus in Q3 2021 and held it in 2 quarters.
  • Soleus Capital Management's Bioventus position peaked at $6.21M in Q4 2021.
  • 105 funds tracked by Wall St. Rank held Bioventus as of Q1 2022.

Based on Soleus Capital Management's 13F filing for Q1 2022, filed 16 May 2022.